Wire · opportunities
Roche details ph. 3 kidney disease win amid blockbuster hopes
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 24 October 2026 · Fusion42 review
Roche's Genentech reported that its phase 3 trial of sefaxersen for IgA nephropathy significantly reduced proteinuria by 43.1% compared to placebo, indicating potential to slow kidney damage progression. The drug, administered monthly by injection, showed a favourable safety profile and aims to provide a new treatment option competing with Novartis' oral Fabhalta in a growing kidney disease market.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You must now assess how monthly injection treatment with sefaxersen changes patient compliance against Novartis' pill option. Investors and partners will watch how the drug’s clean safety profile shapes rapid regulatory approval and market access.
◆ Coverage
1 source · 24 Oct 2026
◆ Related on Wire
◆ Topics